Bcl-2 Expression Inhibits Prostaglandin E2-Mediated Apoptosis in B Cell Lymphomas

Journal of Immunology

Volumn 157, Issue 4, 1996, Pages 1359-1370

  Brown, Deborah M ^a   Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUCLADESINE; DNA; HYBRID PROTEIN; ONCOPROTEIN; PROSTAGLANDIN E2; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE;

APOPTOSIS; B-LYMPHOCYTES; BUCLADESINE; CELL CYCLE; DINOPROSTONE; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENES; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030586674     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Phipps, R. P., S. H. Stein, and R. L. Roper. 1991. A new view of prostaglandin E regulation of the immune response. Immunol. Today 12:349.
2. 2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J. Immunol. 149:2984.
3. 2 promotes B lymphocyte Ig isotype switching to IgE. J. Immunol. 154:162.
4. 2 and IFN-γ. J. Immunol. 148:3943.
5. Narumiya, S., N. Hirata, T. Namba, Y. Hayashi, F. Ushikubi, Y. Sugimoto, M. Negishi, and A. Ichikawa. 1993. Structure and function of prostanoid receptors. J. Lip. Med. 6:155.
6. Fedyk, E. R., J. M. Ripper, D. M. Brown, and R. P. Phipps. 1996. A molecular analysis of PGE receptor (EP) expression on normal and transformed B lympgocytes; coexpression of EP1, EP2, EP3β and EP4. Mol. Immunol. 33:33.
7. 2 receptors on normal and malignant B lymphocytes. Cell. Immunol. 161:79.
8. Stein, S. H., and R. P. Phipps. 1991. Elevated levels of intracellular cAMP sensitize resting B lymphocytes to immune complex-induced unresponsiveness. Eur. J. Immunol. 21:313.
9. Scott, D. W. 1993. B lymphoma models for tolerance: the good, the bad and the apoptotic. Immunomethods 2:105.
10. 2 induces apoptosis in immature normal and malignant B lymphocytes. Clin. Immunol. Immunopath. 63:221.
11. Tsujimoto, Y., and C. M. Croce. 1986. Analysis of the structure, transcripts, and protein products of bcl-2, the gene invovled in human follicular lymphoma. Proc. Nat. Acad. Sci. USA 83:5214.
12. Nunez, G., R. Merino, D. Grillot, and M. Gonzalez-Garcia. 1994. Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol. Today 15:582.
13. Cory, S. 1995. Regulation of lymphocyte survival by the bcl-2 gene family. Ann. Rev. Immunol. 13:513.
14. Vaux, D. L., S. Cory, and J. Adams. 1988. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440.
15. Nuñez, G., L. London, D. Hockenbery, M. Alexander, J. P. McKearn, and S. J. Korsmeyer. 1990. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor deprived hemopoietic cell lines. J. Immunol. 144:3602.
16. Strasser, A., A. W. Harris, and S. Cory. 1991. bcl-2 transgene inhibits T cell death and perturbs thymic self censorship. Cell 67:889.
17. Katsumata, M., R. M. Siegel, D. C. Louie, T. Miyashita, Y. Tsujimoto, P. C. Nowell, M. I. Greene, and J. C. Reed. 1992. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc. Natl. Acad. Sci. USA 89:11376.
18. Strasser, A., S. Whittingham, D. L. Vaux, M. L. Bath, J. M. Adams, S. Cory, and A. W. Harris. 1991. Enforced BCL2 expression in B lymphoid cells prolongs antibody responses and eleicits autoimmune disease. Proc. Natl. Acad. Sci. USA 88:8661.
19. Nakayama, K., K. Nakayama, I. Negishi, K. Kuida, Y. Shinkai, M. C. Louie, L. E. Fields, P. J. Lucas, V. Stewart, F. W. Alt, and D. Y. Loh. 1993. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 261:1584.
20. Mizuguchi, J., W. Tsang, S. L. Morrison, M. A. Beaven, and W. E. Paul. 1986. Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. J. Immunol. 137:2162.
21. Vaux, D. L., H. L. Aguila, and I. L. Weissman. 1992. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell-mediated killing. Int. Immunol. 4:821.
22. 2. Immunomethods 2:261.
23. Duke, R., C. R. Chervenak, and J. J. Cohen. 1983. Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc. Natl. Acad Sci. USA 80:6361.
24. Kamesaki, H., J. A. Zwiebel, J. C. Reed, and J. Cossman. 1994. Role of bcl-2 and IL-5 in the regulation of anti-IgM-induced growth arrest and apoptosis in immature B cell lines: a cooperative regulation model for B cell clonal deletion. J. Immunol. 152:3294.
25. Joseph, L., S. Ezhevsky, and D. W. Scott. 1995. Lymphoma models for B cell activation and tolerance: anti-Immunoglobulin M treatment induces growth arrest by preventing the formation of an active kinase complex which phosphorylates retinoblastoma gene product in G1. Cell Growth Differ. 6:51.
26. Vaux, D. L., and I. L. Weissman. 1993. Neither macromolecular synthesis nor myc is required for cell death via the mechanism that can be controlled by Bcl-2. Mol. Cell. Biol. 13:7000.
27. Phipps, R. P., D. Lee, V. Schad, and G. L. Warner. 1989. E-series prostaglandins are potent growth inhibitors for some B lymphomas. Eur. J. Immunol. 19:995.
28. Hasbold, J., and G. G. B. Klaus. 1990. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur. J. Immunol. 20:1685.
29. Scott, D. W., D. Livnat, C. A. Pennell, and P. Keng. 1986. Lymphoma models for B cell activation and tolerance. III. Cell cycle dependence for negative signaling of WEHI-231 B lymphoma cells by anti-μ. J. Exp. Med. 164:156.
30. Newell, M. K., J. Vanderwall, K. S. Beard, and J. H. Freed. 1993. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc. Natl. Acad. Sci. USA 90:10459.
31. Lomo, J., H. K. Blomhoff, K. Bieske, T. Stokke, and E. B. Smeland. 1995. TGF-β1 and cAMP promote apoptosis in resting human B lymphocytes. J. Immunol. 154:1634.
32. Fang, W., J. J. Rivard, J. A. Ganser, T. W. LeBien, K. A. Nath, D. L. Mueller, and T. W. Behrens. 1995. Bcl-xL rescues WEHI 231 B lymphocytes from oxidant mediated death following diverse apoptotic stimuli. J. Immunol. 155:66.
33. Zhu, L., and C. Anasetti. 1995. Cell cycle control of apoptosis in human leukemic T cells. J. Immunol. 154:192.
34. Merino, R., D. A. M. Grillot, P. L. Simonian, S. Muthukkumar, W. C. Fanslow, S. Bondada, and G. Nunez. 1995. Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells: dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. J. Immunol. 155:3830.
35. Lin, H-J. L., V. Eviner, G. C. Prendergast, and E. White. 1995. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol. 15:4536.
36. McCormack, J. E., V. H. Pepe, R. B. Kent, M. Dean, A. Marshak-Rothstein, and G. E. Sonenshein. 1984. Specific regulation of c-myc oncogene expression in a B cell lymphoma. Proc. Nat. Acad. Sci. USA 81:5546.
37. Fischer, G., S. C. Kent, L. Joseph, D. R. Green, and D. W. Scott. 1994. Lymphoma models for B cell activation and tolerance. X. Anti-m-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc. J. Exp. Med. 179:221.
38. Rock, C. O., J. L. Cleveland, and S. Jackowski. 1992. Macrophage growth arrest by cyclic AMP defines a distinct checkpoint in the mid-G1 stage of the cell cycle and overrides constitutive c-myc expression. Mol. Cell. Biol. 12:2351.
39. 2 on c-Myc and Bcl-2 production and programmed cell death in human lymphocytes. In Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 23. B. Samuelsson, P. W. Ramwell, R. Paoletti, G. Folco, E. Granstrom, and S. Nicosia, eds. Raven Press, New York, p. 457.
40. Sentman, C. L., J. R. Shutter, D. Hockenbery, O. Kanagawa, and S. J. Korsmeyer. 1991. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67:879.
41. Vanhaesebroeck, B., J. C. Reed, D. De Valck, J. Grooten, T. Miyashita, S. Tanaka, R. Beyaert, F. Van Roy, and W. Fliers. 1993. Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. Oncogene 8:1075.
42. Strasser, A. 1995. Life and death during immune development and function: evidence for two distinct killing mechanisms. Curr. Opin. Immunol. 7:228.
43. Cuende, E., J. E. Alés-Martínez, L. Ding, M. Gónzalez-García, C. Martínez-A, and G. Nuñez. 1993. Programmed cell death by bcl-2-dependent and independent mechanisms in B lymphoma cells. EMBO J. 12:1555.
44. Boise, L. H., M. Gónzalez-García, C. E. Postema, L. Ding, T. Lindsten, L. A. Turka, X. Mao, G. Nuñez, and C. B. Thompson. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597.
45. Oltvai, Z. N., C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74:609.